Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2022-04-08 00:00:00 ET · period of report 2022-04-06 · accession 0001209191-22-023856 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-04-08 | 2022-04-06 | PCRX | MOLLOY ANTHONY | Chief Lgl, Compliance Off | M - OptEx | $40.77 | +22.5K | 40.0K | +128% | +$917.4K |
| DM | 2022-04-08 | 2022-04-06 | PCRX | MOLLOY ANTHONY | Chief Lgl, Compliance Off | S - Sale+OE | $76.42 | -22.5K | 24.0K | -48% | -$1.72M |
| DM | 2022-04-08 | 2022-04-06 | PCRX | MOLLOY ANTHONY | Chief Lgl, Compliance Off | M - OptEx | $0.00 | -22.5K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-06 | M | A | 2,500 | $34.38 | 33,050 | D | — | — | |
| 2 | Common | Common Stock | 2022-04-06 | S | D | 3,937 | $77.03 | 20,053 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.58 to $77.57, inclusive. |
| 3 | Common | Common Stock | 2022-04-06 | M | A | 3,000 | $40.34 | 20,550 | D | — | — | |
| 4 | Common | Common Stock | 2022-04-06 | M | A | 10,000 | $44.20 | 30,550 | D | — | — | |
| 5 | Common | Common Stock | 2022-04-06 | S | D | 2,503 | $77.94 | 17,550 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.585 to $78.490, inclusive. |
| 6 | Common | Common Stock | 2022-04-06 | M | A | 7,000 | $38.35 | 40,050 | D | — | — | |
| 7 | Common | Common Stock | 2022-04-06 | S | D | 16,060 | $76.03 | 23,990 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.55 to $76.53, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-04-06 | M | D | 7,000 | $0.00 | 1,750 | D | $38.35 · — to 2028-06-13 | 7,000 Common Stock | (F6) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
| 9 | Derivative | Stock Option (Right to Buy) | 2022-04-06 | M | D | 2,500 | $0.00 | 625 | D | $34.38 · — to 2028-05-02 | 2,500 Common Stock | (F6) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. |
| 10 | Derivative | Stock Option (Right to Buy) | 2022-04-06 | M | D | 10,000 | $0.00 | 0 | D | $44.20 · — to 2027-06-14 | 10,000 Common Stock | (F5) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. |
| 11 | Derivative | Stock Option (Right to Buy) | 2022-04-06 | M | D | 3,000 | $0.00 | 0 | D | $40.34 · — to 2026-06-15 | 3,000 Common Stock | (F5) The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. |